<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02721563</url>
  </required_header>
  <id_info>
    <org_study_id>CMNAER2</org_study_id>
    <nct_id>NCT02721563</nct_id>
  </id_info>
  <brief_title>A Trial of CMNa Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced ESCC</brief_title>
  <official_title>A Perspective Random Phase II Trial of Sodium Glycididazole Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced Squamous Cell Esophageal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Cancer Hospital and Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Cancer Hospital and Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a perspective, multicenter,randomized controlledtrial,Phase 2 study to evaluate the
      efficacy and safety of treatment with CMNa combined with concurrent chemoradiotherapy in
      patients with locally advanced squamous cell esophageal carcinoma . Analyses of primary
      objective (ORR) will be done as defined in the protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary end point of this study is objective response rate.The secondary end point is OS,
      PFS and the safty of drug. The primary hypothesis is the CMNa will improve ORR and thus
      improve OS, PFS. Assuming bilateral a=0.05, statistical power of 80%.The total sample size is
      104 cases.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Esophageal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Sodium Glycididazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sodium Glycididazole：800mg/m2，finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy. Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-6 Cisplatin:20 mg/m²,d1,week 1-6 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.
OR 5-FU: 500 mg / m² / day, divided into D1 ~ D5 for use, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T60Gy/30f,week 1-6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo：dissolved in 100mlphysiological saline(Now with chef),ivgtt,finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy, total 6 weeks course.Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-6 Cisplatin:20 mg/m²,d1,week 1-6 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.
OR 5-FU: 500 mg / m² / day, divided into D1 ~ D5, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T60Gy/30f,week 1-6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Glycididazole</intervention_name>
    <description>Sodium Glycididazole 700mg/m2.Three times a week (once every other one day),before radiation therapy, total 6 weeks.</description>
    <arm_group_label>Sodium Glycididazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo:three times a week (once every other one day),before radiation therapy, total 6 weeks.</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent prior to study entry

          2. Patients with ESCC in upper and middle thoracic segment（stage II-III）confirmed by
             imaging and pathology or cytology, which is unsuitable or refuse surgery;

          3. Capable for chemo-radiotherapy;

          4. The existence of measurable lesions;

          5. ECOG PS of 0 or 1

          6. Possible semi-liquid diet;

          7. Expected lifetime≥3 months

          8. normal bone marrow reserve: ANCcount ≥1500/mm3;platelet count ≥100,000/
             mm3,hemoglobin≥9g/dl

          9. normal hepatic funcion:bilirubin level ≤1.5×ULN;AST/ALT≤1.5×ULN

         10. normal renal function: serum creatinine≤1.5mg/dl and calculated creatinine clearance
             ≥60ml/min

         11. normal cardiac function

         12. Subjects tumor tissue available for the relevant biomarker detection

        Exclusion Criteria:

          1. Female subject who is during pregnancy or lactation, and the subject who have
             fertility don't take effective contraception during study

          2. Any mental illness or nervous system lesions or can't tell treatment response clearly
             (such as cerebrovascular accident sequelae)

          3. Any serious uncontrolled disease and infection, such as severe heart, liver, kidney
             diseases or diabetes, can't complete the treatment plan

          4. Patients who have other malignant lesions, except curable skin cancer (non-melanoma
             skin cancer),carcinoma in situ of cervix or serve disease cured for 5 years

          5. Primary lesions were multifocal

          6. Patients who have obvious esophageal ulcers or have above moderate pains in chest-back
             or have symptoms of esophageal perforation

          7. received anti-cancer treatment of esophageal cancer before the group, including
             surgery, radiotherapy, chemotherapy (induction of chemotherapy before the group is
             greater than or equal to two cycles).

          8. Not esophageal squamous carcinoma confirmed by pathology or cytology

          9. History of active hepatitis

         10. Unable to comprehend the study requirement or who are not likely to comply with the
             study requirements

         11. Significant disease which, in the investigator's opinion, would exclude the patient
             from the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinming Yu, Ph.D, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong Cancer Hospital and Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jinming Yu, Ph.D, M.D</last_name>
    <phone>13806406293</phone>
    <email>sdyujinming@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ligang Xing, Ph.D, M.D</last_name>
    <phone>15553181309</phone>
    <email>xinglg@medmail.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Qianfoshan Hospital of Shandong</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiandong Zhang</last_name>
      <phone>13583123486</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yufeng Cheng</last_name>
      <phone>13869199969</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shandong Cancer Hospital and Institute</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinming Yu</last_name>
      <phone>8653167626891</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jining NO.1 People's Hospital</name>
      <address>
        <city>Jining</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peipei Wu</last_name>
      <phone>15853770581</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liaocheng People 's Hospital</name>
      <address>
        <city>Liaocheng</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingjun Li, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qingdao Center Medical Group</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuezhen Ma</last_name>
      <phone>18660221959</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rizhao City People 's Hospital</name>
      <address>
        <city>Rizhao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yufeng li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fei Cheng People's Hospital</name>
      <address>
        <city>Tai'an</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenyuan Zhao</last_name>
      <phone>13518688689</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>An Qiu People's Hospital</name>
      <address>
        <city>Weifang</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chuandong Wang</last_name>
      <phone>15605368369</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Fourth People's Hospitalof Zibo</name>
      <address>
        <city>Zibo</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiang Zhang</last_name>
      <phone>13345221111</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2016</study_first_submitted>
  <study_first_submitted_qc>March 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2016</study_first_posted>
  <last_update_submitted>February 11, 2017</last_update_submitted>
  <last_update_submitted_qc>February 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Cancer Hospital and Institute</investigator_affiliation>
    <investigator_full_name>Jinming Yu</investigator_full_name>
    <investigator_title>president</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

